Replies to post #48905 on Ocata Therapeutics Inc fka OCAT

[lasers]

IMO ACTC's best course of action is to get a new Phase 2A or Phase 2B trial, whatever the FDA allows, to proceed with the 20/100, 20/80 patients provided that the FDA is totally convinced of the safety of the 150K and 200K Cohorts for the 20/400 patients.

"Should we hop into a Phase IIA trial and power it with more data and see if we can start looking at what happens when you treat 20/100 or 20/80 patients, "